French data is current through early September 2018. All of the data comes from L’Agence nationale de sécurité du médicament et des produits de santé (ANSM), except for the categories Manufacturer Parent Company and Product Classification.
The Parent Company and the Product Classification were added by ICIJ.
The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and France.
데이터 추가 비고
조치
On 13/02/08, the company ZIMMER removed from the market the batches of the references cited in the appendix (15/02/2008) (15 Kb) of the attached recall message, of the medical device called HEMOVAC autotransfusion system and of kits HEMOVAC following a defect of the packaging which can affect the sterility of the devices .. The company ZIMMER warned directly the recipients of the incriminated lots with the message attached (15/02/2008) (23 ko) validated by Afssaps .. This information is addressed to directors and correspondents of materiovigilance for diffusion if necessary to the services concerned. The relevant European Competent Authorities are informed of this measure by the manufacturer.
“The safety of patients has always been, and continues to be, Zimmer Biomet’s top priority and it is our honor to be a leader in this industry for the past 90 years,” Zimmer Biomet told ICIJ in a statement. “We adhere to strict regulatory standards, and work closely with the FDA and all applicable regulatory agencies in each of our regions as part of our commitment to operating a first-rate quality management system across our global manufacturing network. The company added that it is focused on staying at the forefront of innovation and doing right by the millions of patients who rely on the company’s products.